华禧联合科技，历时10年打造的新药技术开发与管理团队，持续提高企业创新能力与国际化程度，已从研发环境、仪器设备、人员配置、质量体系以及管理系统各层面对接国际标准。
华禧联合科技，基于10年的新药开发积累，与专业投资机构一起，通过并购重组，成功实现企业向产业化转型。原料药、口服固体制剂自主开发，生产线对接国际GMP认证，产品主要对接国外市场；鼻喷剂、滴眼剂等液体制剂主要承接国际技术转移及加工合作，生产线对接国际GMP认证。
华禧联合科技，期待通过与**企业的合作，向国际市场提供更具社会效益的高质量药品，使华禧联合科技成为一家倍受尊敬的国际制药企业。
Huaxipharm has new drug technology and management teams with 10 years’ experience. Huaxipharm keep improving creating ability and degree of internationalization, and has complied with international standard on multiple levels, such as R&D environment, lab equipment, human resource allocation, file system and management system.
Huaxipharm, based on 10 years experience of new drug R&D,　achieve the industrialization of the enterprise transformation successfully by a new round of acquisition and reorganization. Huaxipharm’s API and Oral solid preparation are developed independently.　Production line of API and Oral solid preparation is facing international GMP certification and products are designed for foreign markets. For liquid preparation, such as nasal spray and eye drop, Huaxipharm is look for cooperation as technology transfer and OME. Production line of liquid preparation is facing international GMP certification.
Huaxipharm is looking forward to cooperate with outstanding enterprises, and provide high quality medicines of social benefits for international market, thus making Huaxipharm a respected international pharmaceutical company.